02:34 , Apr 16, 2016 |  BC Extra  |  Financial News

Organogenesis raises $30M round

Wound care company Organogenesis Inc. (Canton, Mass.) said it raised about $30 million in a venture round from existing investors. Organogenesis markets Apligraf and Dermagraft to treat diabetic foot ulcers and other chronic wounds. Apligraf...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Organogenesis, Shire deal

Organogenesis purchased wound healing product Dermagraft human fibroblast-derived dermal substitute ( ABH001 ) from Shire. Shire will not receive an upfront payment but is eligible for up to $300 million in milestones based on annual...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Company News

Organogenesis dermatology news

Organogenesis said it is reducing headcount by an undisclosed number after the Centers for Medicare & Medicaid Services (CMS) said it will reduce its reimbursement for the company's wound care product Apligraf to $1,371 from...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Organogenesis, Novartis regulatory update

Canada granted Novartis marketing approval for ORG's Apligraf Human Skin Equivalent. According to ORG, which will manufacture the product for Canadian distribution, the approval was based on ORG's 1996 U.S. pivotal trial of Apligraf in...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Organogenesis, Novartis Pharmaceuticals Canada Inc. sales and marketing update

Novartis began Canadian sales of ORG's Apligraf human skin equivalent to treat venous ulcers. ORG will manufacture the product, which is under review at the FDA. Organogenesis Inc. (ORG), Canton, Mass.   Novartis Pharmaceuticals Canada...
07:00 , Mar 12, 2012 |  BC Week In Review  |  Clinical News

Gintuit regulatory update

FDA approved a BLA for Organogenesis' Gintuit (formerly CelTx) to treat mucogingival conditions. The product is indicated for topical application to a surgically created vascular wound bed. Last year, FDA's Cellular, Tissue and Gene Therapies...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

CelTx regulatory update

FDA's Cellular, Tissue and Gene Therapies advisory committee voted 15-0 that data provided for Organogenesis' CelTx demonstrates effectiveness of the product for the treatment of surgically created gingival surface defects in adults. The committee also...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Clinical News

CelTx regulatory update

Organogenesis filed a PMA with FDA for CelTx to regenerate oral soft tissue in patients with gingival recession. The product is a cellular construct comprised of human fibroblasts, keratinocytes and extracellular matrix proteins. Organogenesis Inc....
07:00 , Aug 6, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Wounds Hypoxia-inducible factor 1a (HIF1A); VEGF Studies in cell culture and in mice suggest that the iron chelating agent deferoxamine could treat diabetic wounds. In...
08:00 , Feb 19, 2009 |  BC Innovations  |  Targets & Mechanisms

Beta-blocking wounds

Researchers at the University of California, Davis think they may have identified a new indication for β-blockers: wound healing. 1 Although the safety profile of the drugs in cardiovascular disorders provides an incentive to repurpose...